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Abstract: Background and objectives: To explore the impacts that Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome (ME/CFS) has on the patient and their family members using the WHOQOL-BREF
(Abbreviated World Health Organisation Quality of Life questionnaire) and FROM-16 (Family Reported
Outcome Measure-16) quality of life assessments. Materials and Methods: A quantitative research study
using postal questionnaires was conducted. A total of 39 adult volunteers expressed an interest in
participating in the study: 24 returned appropriately completed questionnaires. Patients with ME/CFS
completed the WHOQOL-BREF and up to four of their family members completed the FROM-16
questionnaire. Results: ME/CFS negatively affects the quality of life of the patient (median scores
WHOQOL-BREF: Physical health = 19, Psychological = 44, Social relationships = 37.5, Environment = 56,
n = 24) and their family members’ quality of life (FROM-16: Emotional = 9.5, Personal and social = 11.5,
Overall = 20.5, n = 42). There was a significant correlation between the patient’s reported quality of
life scores and their family members’ mean FROM-16 total scores. Conclusions: This study identifies
the major impact that having an adult family member with ME/CFS has on the lives of partners and
of other family members. Quality of life of ME/CFS patients was reduced most by physical health
compared to the other domains. Quality of life of family members was particularly impacted by worry,
family activities, frustration and sadness. This highlights the importance of measuring the impact on
the lives of family members using tools such as the FROM-16 in the ME/CFS clinical encounter and
ensuring appropriate support is widely available to family members.
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1. Introduction
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has profound im-
pacts on the lives of those affected, but little is known about the impact experienced
by partners and other family members. This hidden family burden is often ignored or
unrecognised by health care workers.
ME/CFS is a complex, multisystem disease involving neurological, immunological,
autonomic, and energy metabolism impairments [1]. Symptoms include post-exertional
malaise (PEM), orthostatic intolerance, cognitive difficulties and unremitting fatigue [2].
ME/CFS is diagnosed based on clinical criteria, due to the absence of a known biomarker.
The aetiology is unclear and there is no definitive pharmacological treatment; current
treatment options target symptoms, rather than an underlying cause [2]. This lack of
knowledge and evidence concerning diagnosis, aetiology and therapy add an additional
burden to the practical issues experienced by those living with someone with ME/CFS.
Health-related quality of life (QoL) in patients with ME/CFS is significantly lower
than in healthy controls and patients with other chronic illnesses [3]. Some studies have
explored ME/CFS in paediatric patients and the impact on their mothers [4] and siblings [5].
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However, there are no studies to date which have explored the impact of ME/CFS on both
adult patients’ QoL and their family members’ QoL using validated questionnaires.
It is important to identify the extent to which the QoL of partners and family members
of adults with ME/CFS is affected. Such knowledge may appropriately influence manage-
ment decisions and also highlight areas of support that are required for both the patient
and the family members. Measurement of QoL may thereby have the potential to enhance
the quality of care of patients and their families.
The aim of the study was to measure the impact of ME/CFS on the patient and
family using the WHOQOL-BREF (Abbreviated World Health Organisation Quality of Life
questionnaire) and FROM-16 (Family Reported Outcome Measure-16) questionnaires. In
families where patients reported a poorer QoL, we hypothesised that there would be a
significant impact on the family member’s QoL.
2. Materials and Methods
Ethical approval was granted by the Cardiff University School of Medicine Research
Ethics Committee on 1 March 2019 (reference number 19/29).
Information regarding the study was posted on the Welsh Association of ME & CFS
Support charity website and social media pages, through which patients made contact.
Patient volunteers who expressed an interest in participating were sent packs in the post
containing: research information leaflets, consent forms, one WHOQOL-BREF question-
naire for the patient and four FROM-16 questionnaires for up to four of their family
members. Participants were excluded if the patient did not have a formal diagnosis of
ME/CFS, if questionnaires were incomplete, or if the patient or family member were under
the age of 18 years. All included patients and family members consented to participating
in the study.
Participant information and questionnaire responses were recorded on separate
password-protected Excel spreadsheets on a Cardiff University computer. WHOQOL-
BREF questionnaires included a two-digit code number and letter A (e.g., 01 A). Each
FROM-16 questionnaire included a three-digit code and letter B (e.g., 01.1 B). Each family
received a different number. This coding ensured responses remained anonymous but still
grouped when interpreting the data.
The WHOQOL-BREF is a 26-item questionnaire, which measures the impact of an
illness on a patient’s QoL [6] and is suitable for measuring the impact of ME/CFS [7].
Patients are assessed across four domains: Physical Health, Psychological, Social Rela-
tionships and Environment. A lower score in the WHOQOL-BREF indicates a poorer
QoL. This questionnaire includes two additional questions regarding the patient’s overall
perception of their QoL and their health satisfaction. Each question has a five-point Likert
interval scale where patients rate their response from ‘Not at all’ (1 point) to ‘An extreme
amount’ (5 points). Patients were also asked to self-time how long it took to answer the
WHOQOL-BREF.
The FROM-16 is a 16-item questionnaire designed to assess the impact of a disease
on the patient’s partner and family members [8]. The maximum score is out of 32, with a
higher score indicating a greater impact on the family member’s QoL. The questionnaire
consists of two domains: Emotional (Part 1) and Personal and Social Life (Part 2). Each
answer is graded on a three-point scale consisting of ‘Not at all’, ‘A little’ and ‘A lot’.
Statistical averages (mean, median, range, standard deviation) were used to assess the
data collected by the questionnaires. Spearman’s rank correlation coefficient was used to
measure the strength of the correlation between different aspects of the WHOQOL-BREF
and the mean FROM-16 total scores.
3. Results
Of 39 questionnaires posted in response to expression of interest, 29 were returned,
giving a response rate of 74%. Five were excluded from analysis due to incomplete
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questionnaires and a self-reported diagnosis, resulting in 24 questionnaire packs available
for analysis (24 WHOQOL-BREF questionnaires and 42 FROM-16 questionnaires).
The mean number of family members that participated within each family was 1.75
(mode = 1, median = 1) (Figure 1). The range was 1–4.
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The median time it took patients to complete the WHOQOL-BREF questionnaire
was 5–10 min (range from two minutes to one week). One patient did not provide this
information and so was excluded from this analysis. Five of the 23 patients (21.7%) required
assistance with completing their questionnaire.
One patient did not answer one of the WHOQOL-BREF questions in the Environment
domain. We calculated the mean Environment score based on the other participants’
answers in this domain, and then used this score to complete the question.
All patients rated their QoL as either ‘Very poor’, ‘Poor’, or ‘Neither poor nor good’ in
Question 1 of the WHOQOL-BREF. Similarly, they were either ‘Very dissatisfied’ ‘Dissatis-
fied’, or ‘Neither satisfied nor dissatisfied’ with their health, measured using Question 2.
The responses to both questions had a Spearman’s rank correlation coefficient (rs) of 0.50
[p(2-tailed) = 0.03], showing a statistically significant, strong correlation between patient
QoL and health satisfaction.
The mean scores of parents, children and partners and spouses (Table 2) are very
similar (range 18.0–20.1). Of the other respondents, only five siblings and grandparents
responded, with a mean score of 27.0.
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Table 1. Patient and family member demographics.
Patient Demographics (n = 24)
Frequency Percentage (%)
Gender:
Female 18 75
Male 6 25
Marital Status:
Single 6 25
Married 13 54
Living as married 3 13
Separated 1 4
Divorced 1 4
Widowed 0 0
None at all 0 0
Primary School 0 0
Secondary School 6 25
Tertiary 18 75
Family Member Demographics (n = 41)
Frequency Percentage (%)
Gender
Female 18 43.9
Male 23 56.1
Relationship to Patient:
Mother 11 26.8
Father 4 9.8
Spouse 12 29.3
Partner 4 9.8
Son 3 7.3
Daughter 2 4.9
Brother 2 4.9
Sister 1 2.4
Grandmother 1 2.4
Grandfather 1 2.4
Table 2. Mean FROM-16 (Family Reported Outcome Measure-16) scores of family members.
Respondents Number of Replies Mean FROM-16
1 Parents 15 20.1
2 Children 5 18.0
3 Partners and Spouses 16 19.1
4 Siblings and grandparents 5 27.0
Family members, on average, scored 8.8 (max = 12) in the FROM-16 emotional domain,
and 11.1 (max = 20) in the personal and social life domain (Table 3). The average overall
FROM-16 score was 19.9 (n = 42). Family members are greatly affected by the ME/CFS,
with no floor effect in either of the FROM-16 domains.
Table 3 shows the mean and median score for each of the 16 FROM-16 questions, and
the rank of each question, based on mean scores. The median score was 2 for 6 questions:
these were (given in descending order of score magnitude): questions 1 (worried), 10
(family activities), 4 (frustrated), 3 (sad), 11 (holidays), 15 (expenses). The median score for
the other 10 questions was 1.
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Table 3. The rank of each question based on the mean score and the median score of each question.
Rank 1 2 3 4 5 6 7 7 9 10 10 12 13 13 15 16
Question No. 1 10 4 3 11 15 5 6 2 7 14 13 12 16 8 9
Mean FROM-16 Score 1.80 1.76 1.70 1.60 1.51 1.34 1.29 1.29 1.10 1.07 1.07 0.96 0.86 0.86 0.83 0.76
Median FROM-16 Score 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1
For patients, the average score for the physical health domain (21.8) in the WHOQOL-
BREF was significantly lower compared to each of the other domains (psychological = 40.9,
social relationships = 40.8, environment = 54.7, n = 24) (Table 4).
Table 4. Average results from both the FROM-16 (Family Reported Outcome Measure-16) and WHOQOL-BREF (Abbreviated
World Health Organisation Quality of Life) questionnaires.
Questionnaire Domain Mean
Sample
Standard
Deviation
Median Range Floor Effect (%) Ceiling Effect (%)
FROM-16
(n = 42)
Emotional (max 12) 8.8 2.7 9.5 2–12 - ** 16.7
Personal and social life (max 20) 11.1 5.2 11.5 1–20 - 2.4
Overall score (max 32) 19.9 7.2 20.5 3–31 - -
WHOQOL-BREF
(n = 24)
Physical health * 21.8 12.5 19 0–56 4.2 -
Psychological * 40.9 14.7 44 13–69 - -
Social relationships * 40.8 24.5 37.5 0–100 4.2 4.2
Environment * 54.7 14.1 56 19–94 - -
* Transformed score (max 100)]. The maximum FROM-16 total score is 32. The emotional and personal and social score are out of 12 and 20
respectively. ** Floor effect – all family members recorded some impact on quality of life
A statistically significant correlation [p(2-tailed) = 0.05] was found between the QoL of
the patient and that of the family members, calculated from Question 1 of the WHOQOL-
BREF and the mean FROM-16 total scores (rs =  0.41) (Table 5). There was a negative
correlation due to the different scoring directions of the two questionnaires.
Statistically significant, negative correlations were found between Physical Health
(domain 1) of the WHOQOL-BREF and the mean FROM-16 total score and between the
Environment (domain 4) and mean FROM-16 total score. Table 5 shows the Spearman’s
rank correlation coefficients for the domains with the 2-tailed probability level.
Table 5. Spearman’s rank correlation coefficient and probability level of correlation between the
mean FROM-16 total scores and each of the WHOQOL-BREF domains.
WHOQOL-BREF Domain Correlated
with the Mean FROM-16 Total Score.
Spearman’s Rank
Correlation Coefficient (rs)
p(2-Tailed) Test
Domain 1: Physical Health  0.510 0.01
Domain 2: Psychological  0.092 0.67
Domain 3: Social Relationships  0.323 0.12
Domain 4: Environment  0.453 0.03
4. Discussion
Our results confirm ME/CFS has a major negative impact on both the patient and
their family members’ QoL. There was no floor effect in any of the FROM-16 responses,
exemplifying some degree of impact on every single family member who participated.
With a mean total FROM-16 score of 19.9, the negative impact on family members’
QoL was significantly higher (mean = 19.9 SD = 7.2 n = 42) compared to previous FROM-16
scores of family members of patients with 25 other diseases (mean = 12.3, SD = 7.5, n = 120,
p < 0.001) [8].
The statistically significant correlation between Question 1 of the WHOQOL-BREF
and the mean FROM-16 total scores, confirms our hypothesis that in ME/CFS patients, a
poorer QoL impacts greatly on their family members’ QoL. Patient’s family members’ QoL
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is an important concept and has shown to be adversely affected in a wide range of medical
specialities, from dermatology [9] to oncology [10] whereas in certain conditions such as
urinary stones, there has been a negligible impact on family members [11].
From this low number of respondents, there appears to be no obvious signal suggest-
ing that there might be differences in QoL impact experienced by relatives of different
relationship with the affected person. However, the few siblings and grandparents scored
more highly. Mothers and female partners/spouses scored marginally higher than fathers
and male partners/spouses. The minimal clinically important score difference (MCID)
for FROM-16 has not yet been determined, but the MCID of a measure is usually in the
order of 10–15% of the maximum score for that measure, i.e., a score change here of three
to five. If that is the case, the differences between mean scores of parents, children and
partners and spouses would not have reached the MCID level. However, the mean scores
for the individual FROM-16 questions reveal which aspects of family member’s lives were
most affected by having a family member with ME/CFS: these were worry, family activi-
ties, frustration and sadness. This emphasises the importance of providing appropriate
psychological support and practical advice, including financial advice, to family members.
The finding that, for patients, the average score for the physical health domain was
significantly lower compared to each of the other domains has also been shown within
other ME/CFS research studies using the Medical Outcomes Study Short Form-36 Health
Survey. All scores regarding physical function were significantly lower when compared to
healthy controls and other illness groups [12,13]. A strong correlation was found between
the WHOQOL-BREF ‘Physical Health’ domain and the mean FROM-16 total scores.
Also highlighted in our results, was a correlation between the WHOQOL-BREF ‘Envi-
ronment’ domain and the mean FROM-16 total scores. Weak correlations with the other
WHOQOL-BREF domains (Psychological and Social Relationships) and the mean FROM-16
total scores were expected as these aspects of QoL are not fully addressed in the FROM-16
questionnaire.
Limitations of this study include that questionnaires were not anonymous within
each family—patients could see what their family members had answered and vice versa.
Consequently, some participants may have over- or understated some of their responses.
Self-reported questionnaires also carry their own risk of bias, for example, answering
questions with socially-desirable answers. Some families had more than one family member
with ME/CFS. This could confound the results. Different domains were measured between
the questionnaires, therefore some of the domains were not expected to significantly
correlate with the FROM-16 scores. The recruitment method used creates several biases
that must be taken into account when interpreting the data. Respondents had to be
motivated to be a member of a patient support group and were also part of an online
environment. It is possible that these biases may have resulted in those patients and
family members who were more highly educated, resourceful and dissatisfied as well as
more severely affected were over-represented. This was a limitation noted by Hvidberg
et al. who received questionnaire responses from 105 participants on a health related QoL
(HRQoL) via the national ME/CFS patient association [3].
The median time of 5–10 min for patients to complete the WHOQOL-BREF question-
naire demonstrates that this could be a useful tool in a clinical or outpatient setting.
Positive aspects of the study included that this was the first attempt to measure the
impact of adult ME/CFS on the QoL of family members using validated questionnaires. If
indeed more severely affected patients are over-represented in this study, this would be
an important advantage, as such patients are often poorly represented in studies, and the
burden of ME/CFS may therefore be significantly underestimated [14].
5. Conclusions
To the best of our knowledge, this is the first study to measure the QoL in family
members and adult patients with ME/CFS using validated questionnaires. There is a
significant correlation between patient’s QoL and their family members’ QoL. This was a
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small exploratory study but provides sufficient evidence to support larger scale research to
provide more robust evidence.
At present there is very little support available to family members of patients with
ME/CFS. This study provides evidence of the major impact that this condition has on
the QoL of family members. This lays down a challenge to the health care services to
address these issues and to identify ways in which the secondary impact of ME/CFS may
be alleviated.
Author Contributions: Conceptualization, N.M., A.Y.F. and J.V.; methodology, N.M., A.Y.F. and J.V.;
formal analysis, E.B., N.M., A.Y.F. and J.V.; investigation, E.B.; data curation, E.B.; writing—original
draft preparation, E.B.; writing—review and editing, E.B., N.M., A.Y.F. and J.V.; supervision, N.M.,
A.Y.F. and J.V.; project administration, J.V.; no external funding. All authors have read and agreed to
the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Cardiff University School of Medicine Research Ethics
Committee on 1 March 2019 (reference number 19/29).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author. The data are not publicly available, patients have given consent for use of
their anonymous data in this study.
Acknowledgments: The authors would like to thank Jan Russell at the Welsh Association of ME & CFS
Support and the ME/CFS patients and their families for volunteering to participate in this research.
Conflicts of Interest: A.Y.F. is joint copyright holder of the FROM-16. N.M. has given testimony to
NICE and Ono Pharmaceutical, N.M. is also Chair of the Education Working Group of the CFS/ME
Research Collaborative (CMRC) and is a member of Forward ME. J.V. has been on a paid advisory
board for Amgen and has received honoraria from L’Oréal outside of this submission. E.B. has no
conflicts of interest to declare.
References
1. US ME/CFS Clinician Coalition. Available online: https://www.omf.ngo/2019/09/01/new-guidelines-for-diagnosing-and-
treating-me-cfs/ (accessed on 26 November 2020).
2. Baker, R.; Shaw, E. Diagnosis and management of chronic fatigue syndrome or myalgic encephalomyelitis (or encephalopathy):
Summary of NICE guidance. BMJ 2007, 335, 446–448. [CrossRef] [PubMed]
3. Hvidberg, M.F.; Brinth, L.S.; Olesen, A.V.; Petersen, K.D.; Ehlers, L. The health-related quality of life for patients with myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS). PLoS ONE 2015, 10, e0132421. [CrossRef] [PubMed]
4. Missen, A.; Hollingworth, W.; Eaton, N.; Crawley, E. The financial and psychological impacts on mothers of children with chronic
fatigue syndrome (CFS/ME). Child Care Heatlh Dev. 2012, 38, 505–512. [CrossRef] [PubMed]
5. Velleman, S.; Collin, S.M.; Beasant, L.; Crawley, E. Psychological wellbeing and quality-of-life among siblings of paediatric
CFS/ME patients: A mixed-methods study. Clin. Child Psychol. Psychiatry 2016, 21, 618–633. [CrossRef] [PubMed]
6. Harper, A.; Power, M. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol. Med.
1998, 28, 551–558.
7. Roberts, D. Chronic fatigue syndrome and quality of life. Patient Relat. Outcome Meas. 2018, 9, 253–262. [CrossRef] [PubMed]
8. Golics, C.J.; Basra, M.K.A.; Finlay, A.Y.; Salek, S. The development and validation of the Family Reported Outcome Measure
(FROM-16)© to assess the impact of disease on the partner or family member. Qual. Life Res. 2014, 23, 317–326. [CrossRef]
[PubMed]
9. Basra, M.; Finlay, A.Y. The family impact of skin diseases: The Greater Patient concept. Br. J. Dermatol. 2007, 156, 929–937.
[CrossRef] [PubMed]
10. Lee, H.J.; Park, E.C.; Seung Ju, K.; Lee, S.G. Quality of life of family members living with cancer patients. Asian Pac. J Cancer Prev.
2015, 16, 6913–6917. [CrossRef] [PubMed]
11. Raja, A.; Wood, F.; Joshi, H.B. The impact of urinary stone disease and their treatment on patients’ quality of life: A qualitative
study. Urolithiasis 2020, 48, 227–234. [CrossRef] [PubMed]
12. Lowry, T.J.; Pakenham, K.I. Health-related quality of life in chronic fatigue syndrome: Predictors of physical functioning and
psychological distress. Psychol. Health Med. 2008, 13, 222–238. [CrossRef] [PubMed]
Medicina 2021, 57, 43 8 of 8
13. Nacul, L.C.; Lacerda, E.M.; Campion, P.; Pheby, D.; de LDrachler, M.; Leite, J.C.; Poland, F.; Howe, A.; Fayyaz, S.; Molokhia, M.
The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. BMC
Public Health 2011, 11, 402. [CrossRef] [PubMed]
14. Davenport, T.E.; Stevens, S.R.; Van Ness, J.M.; Stevens, J.; Snell, C.R. Checking our blind spots: Current status of research evidence
summaries in ME/CFS. Br. J. Sports Med. 2019, 53, 1198. [CrossRef] [PubMed]
